Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Azilsartan medoxomil and chlorthalidone

(Edarbyclor®)

Edarbyclor®

Drug updated on 12/11/2024

Dosage FormTablet (oral; azilsartan/chlorthalidone: 40/12.5 mg and 40/25 mg)
Drug ClassAngiotensin II receptor blockers and thiazide-like diuretics
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy
  • Indicated for the treatment of hypertension, to lower blood pressure as initial therapy in patients likely to need multiple drugs to help achieve blood pressure goals

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • The combination of azilsartan medoxomil (AZL-M) and chlorthalidone (CLD) significantly reduces systolic blood pressure, with studies showing a reduction of -35.1 mm Hg for AZL-M/CLD compared to -29.5 mm Hg for AZL-M with hydrochlorothiazide in clinical settings.
  • In a cohort of 153 patients with chronic kidney disease, AZL-M/CLD showed improved adherence compared to other single-pill combination agents, indicating enhanced compliance within this population.
  • Among patients with essential hypertension, the combination of AZL-M and CLD demonstrated strong antihypertensive effectiveness, especially in lowering blood pressure and achieving adherence in chronic kidney disease patients.
  • The most commonly reported adverse events for azilsartan medoxomil include dizziness, headache, fatigue, upper respiratory tract infection, and urinary tract infection.
  • Chlorthalidone, compared to hydrochlorothiazide, is associated with higher serum uric acid levels and lower potassium levels, presenting specific safety concerns.
  • There is no population types or subgroups information available in the reviewed studies.